Inventor · disambiguated record
Martin Maier
Also filed as: MAIER MARTIN · MAIER MARTIN A
126 granted patents·79 pending applications·3,203 citations·filing 1999–2025
99Inventor score
Files withALNYLAM PHARMACEUTICALS INC162ARBUTUS BIOPHARMA CORP10ISIS PHARMACEUTICALS INC9MANOHARAN MUTHIAH5GENZYME CORP3
Top patents by PatentIndex Score
205 records- 0199US10806791B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·14 cites·12 claims
- 0299US9796974B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Oct 24, 2017·119 cites·30 claims
- 0399US9682139B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2015·Granted Jun 20, 2017·46 cites·20 claims
- 0499US9352048B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted May 31, 2016·112 cites·20 claims
- 0599US8106022B2Carbohydrate conjugates as delivery agents for oligonucleotidesMANOHARAN MUTHIAH·Filed 2008·Granted Jan 31, 2012·588 cites·21 claims
- 0699US6878805B2Peptide-conjugated oligomeric compoundsISIS PHARMACEUTICALS INC·Filed 2002·Granted Apr 12, 2005·218 cites·38 claims
- 0798US11679158B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jun 20, 2023·7 cites·13 claims
- 0898US11633479B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·24 claims
- 0998US11633480B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·28 claims
- 1098US11612657B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 28, 2023·9 cites·30 claims
- 1198US11590229B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Feb 28, 2023·11 cites·29 claims
- 1298US11406716B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·8 cites·21 claims
- 1398US11382979B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jul 12, 2022·18 cites·30 claims
- 1498US11246933B1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Feb 15, 2022·30 cites·28 claims
- 1598US11110174B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Sep 7, 2021·10 cites·20 claims
- 1698US10668170B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 2, 2020·22 cites·22 claims
- 1798US10612024B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·15 cites·35 claims
- 1898US10612027B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·26 cites·25 claims
- 1998US10369226B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 6, 2019·25 cites·42 claims
- 2098US10233448B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 19, 2019·37 cites·40 claims
- 2198US9867882B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jan 16, 2018·33 cites·29 claims
- 2298US9399775B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jul 26, 2016·51 cites·36 claims
- 2398US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
- 2498US9061063B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jun 23, 2015·41 cites·32 claims
- 2598US9051567B2Methods for increasing efficacy of lipid formulated siRNAFITZGERALD KEVIN·Filed 2010·Granted Jun 9, 2015·104 cites·25 claims
- 2698US9012498B2Biodegradable lipids for the delivery of active agentsMANOHARAN MUTHIAH·Filed 2011·Granted Apr 21, 2015·104 cites·41 claims
- 2798US8999351B2Lipids and compositions for the delivery of therapeuticsMANOHARAN MUTHIAH·Filed 2009·Granted Apr 7, 2015·102 cites·15 claims
- 2898US8828956B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Sep 9, 2014·224 cites·16 claims
- 2998US8642076B2Lipid containing formulationsMANOHARAN MUTHIAH·Filed 2011·Granted Feb 4, 2014·155 cites·28 claims
- 3098US8450467B2Carbohydrate conjugates as delivery agents for oligonucleotidesMANOHARAN MUTHIAH·Filed 2011·Granted May 28, 2013·227 cites·21 claims
- 3197US11286486B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Mar 29, 2022·8 cites·28 claims
- 3297US11034958B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·7 cites·17 claims
- 3397US9682922B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 20, 2017·39 cites·18 claims
- 3497US9370581B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Jun 21, 2016·24 cites·20 claims
- 3597US9290760B2Modified iRNA agentsRAJEEV KALLANTHOTTATHIL G·Filed 2011·Granted Mar 22, 2016·100 cites·33 claims
- 3697US7713944B2Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cellsISIS PHARMACEUTICALS INC·Filed 2005·Granted May 11, 2010·42 cites·18 claims
- 3796US11873491B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 16, 2024·2 cites·32 claims
- 3896US11504391B1Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 22, 2022·18 cites·42 claims
- 3996US11401517B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Aug 2, 2022·6 cites·24 claims
- 4096US11071784B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jul 27, 2021·5 cites·1 claims
- 4196US10988768B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Apr 27, 2021·3 cites·21 claims
- 4296US10117941B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2017·Granted Nov 6, 2018·12 cites·14 claims
- 4396US9850488B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Dec 26, 2017·11 cites·62 claims
- 4496US9701963B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Jul 11, 2017·9 cites·32 claims
- 4596US9370582B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Jun 21, 2016·23 cites·20 claims
- 4696US9127274B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS·Filed 2013·Granted Sep 8, 2015·51 cites·62 claims
- 4795US11400158B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Aug 2, 2022·1 cites·30 claims
- 4895US10821186B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2018·Granted Nov 3, 2020·4 cites·24 claims
- 4995US10683501B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 16, 2020·8 cites·28 claims
- 5095US10570393B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·17 cites·46 claims
Showing the top 50 of 205 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Martin Maier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →